Cellectis (NASDAQ:CLLS) Releases Earnings Results, Misses Estimates By $0.41 EPS

Cellectis (NASDAQ:CLLS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.41), FiscalAI reports. The company had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $15.61 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Cellectis Price Performance

Cellectis stock traded down $0.15 during midday trading on Friday, reaching $1.18. The company’s stock had a trading volume of 33,967 shares, compared to its average volume of 59,277. The firm has a market capitalization of $118.30 million, a PE ratio of -1.81 and a beta of 3.21. Cellectis has a fifty-two week low of $0.88 and a fifty-two week high of $5.45. The stock’s 50 day simple moving average is $1.49 and its 200 day simple moving average is $2.94. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37.

Analyst Ratings Changes

Several brokerages have recently weighed in on CLLS. Weiss Ratings raised shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Citizens Jmp cut shares of Cellectis from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 15th. Barclays cut shares of Cellectis from an “overweight” rating to an “underweight” rating and cut their price target for the stock from $9.00 to $1.30 in a report on Wednesday, September 16th. Wells Fargo & Company reduced their price objective on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday, September 15th. Finally, Robert W. Baird lowered their price objective on Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Cellectis has an average rating of “Hold” and an average target price of $5.46.

About Cellectis

Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.